Skip to main content
. 2022 Sep 6;10(3):60. doi: 10.3390/diseases10030060

Figure 2.

Figure 2

(A) Overview of adaptive and innate immune checkpoint molecules involved in the antitumor response, present on T cells and antigen-presenting cells, such as dendritic cells and macrophages. Created with BioRender.com. (Abbreviations: PD-1, programmed death-1; PDL-1, programmed cell death ligand 1; TIM-3, T cell immunoglobulin and mucin domain-containing protein 3; Gal-9, galectin 9; TIGIT, T cell immunoreceptor with immunoglobulin and ITIM domain; PVR, Poliovirus receptor; LAG-3, lymphocyte-activation gene 3; FGL1, fibrinogen-like protein 1; MHC-I, major histocompatibility complex I; MHC-II, major histocompatibility complex II; Siglec-10, sialic acid binding Ig like lectin 10; SIRPα, signal regulatory protein alpha, APMAP, adipocyte plasma membrane-associated protein; GPR84, G-protein coupled receptor 84; LILRB, leukocyte immunoglobulin-like receptor. Figure generated using BioRender.com. (B) Timeline of U.S. FDA-approved immune checkpoint inhibitors (ICI) for various cancers. Data source: www.cancerresearch.org, accessed on 25 June 2022. (Abbreviations: MCC, merkel cell carcinoma; PMBCL, primary mediastinal large B-cell lymphoma; RCC, renal cell carcinoma; NSCLC, non-small lung cell carcinoma; HNSCC, head and neck squamous cell carcinoma; SCLC, small-cell lung carcinoma).